Impact of Influenza/RSV PCR Point-of-care Testing in the Emergency Medical Service.

Influenza Clinical Trial

Official title:

Impact Study of a Rapid Diagnosis of Influenza in the Emergency Medical Service During the 2018-2019 Epidemic Season

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04048369
• Other study ID #: RBHP 2018 HENQUELL
• Secondary ID: 2018-A02478-47
• Status: Active, not recruiting
• Phase: N/A
• Start date: January 17, 2019
• Est. completion date: December 31, 2019

Study information

• Verified date: June 2019
• Source: University Hospital, Clermont-Ferrand
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to compare Emergency Department patients who undergo influenza and RSV PCR testing using an FDA-approved point-of-care device (Cepheid Xpert® Xpress Flu/RSV) located in the ED, to patients who undergo influenza and RSV PCR testing at the core laboratory.

The principal purpose is to determine if the time spent in the ED is different in the group undergoing POC influenza testing compared to those undergoing laboratory-based influenza testing.

Description:

• This study will be conducted during the influenza's epidemic season. The start and the end of this study will be determined using national epidemic bases (national reference center for inluenza in Lyon).

• Collection of consent of eligible patients after medical information by a senior emergency physician

• Sampling = nasopharyngeal swabbing for all patients using usual testing or point-of-care testing

• first arm : performing the test at the adult emergency department 24h/24

• second arm : sending the test to the virology laboratory and realization during working hours

• Collection of clinical data : a specific standardized questionnaire is used, as soon as the patient is included and until he leaves the emergency medical service, to collect clinical data and the time taken to take care of the patient

In order to reduce the bias of this study, it has been established :

After verification of the eligibility criteria and obtaining the written consent of the patient, a randomization procedure will be initiated for the patient. Randomization will be centralized at the DRCI of Clermont-Ferrand University Hospital. Patients will be randomly assigned to one of the study groups by means of individual block randomization. A document describing the randomization procedure will be kept confidentially in the DRCI of Clermont-Ferrand University Hospital;

• The collection of data will be prospective.

A listing of patients opposing to the study's participation to verify that their characteristics are homogeneous to the general population The choice of the Genexpert® automaton used in the "point of care testing" arm whose principle of operation requires a minimum of manipulations (<2 minutes) and does not generate inter-operator variability Statistical analyzes will be performed with the Stata software (version 13, StataCorp, College Station). All statistical tests will be carried out at the risk of error of the first species α of 5%. Part of the analysis of the secondary endpoints should be primarily exploratory in nature. As discussed by Feise in 2002 (Feise RJ, Do 2: 8), the adjustment of the risk of error of 1st species will not be proposed systematically, but case by case in view of clinical considerations and not just statistical ones.

Continuous variables will be presented as mean and standard deviation, subject to the normality of their distribution (Shapiro-Wilk test if necessary). In case of non-normality, they will be presented as median, quartiles, and extreme values. The qualitative variables will be expressed in numbers and percentages associated. Graphic representations will be associated with these analyzes as much as possible.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 431
• Est. completion date: December 31, 2019
• Est. primary completion date: March 14, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria :

• 18 years old and older

• coming in the emergency medical service

• during the influenza epidemic period

• with influenza symptoms

• whose support requires virologic confirmation

• people having given their consent

Exclusion criteria :

• pregnant or breast feeding women

• patient unable to give consent

• tutorship or curatorship or under the protection of justice

• patient non registered in the social security system

Related Conditions & MeSH terms

• Emergencies
• Influenza
• Influenza, Human

Intervention

Diagnostic Test:
• Rapid diagnosis of influenza in the emergency medical service
Comparison at the University Hospital of Clermont-Ferrand of a test performed in the Adult Emergencies Department by the nursing staff (point-of-care testing) to a test carried out in the core laboratory (classical testing).

Locations

Country	Name	City	State
France	CHU de Clermont-Ferrand	Clermont-Ferrand	Auvergne

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Clermont-Ferrand

Country where clinical trial is conducted

France, 

References & Publications (7)

Banerjee D, Kanwar N, Hassan F, Essmyer C, Selvarangan R. Comparison of Six Sample-to-Answer Influenza A/B and Respiratory Syncytial Virus Nucleic Acid Amplification Assays Using Respiratory Specimens from Children. J Clin Microbiol. 2018 Oct 25;56(11). pii: e00930-18. doi: 10.1128/JCM.00930-18. Print 2018 Nov. — View Citation

Bennett S, MacLean A, Gunson R. Verification of Cepheid Xpert Xpress Flu/RSV assay for use with gargle samples, sputa and endotracheal secretions. J Hosp Infect. 2019 Jan;101(1):114-115. doi: 10.1016/j.jhin.2018.07.016. Epub 2018 Jul 17. — View Citation

Brendish NJ, Malachira AK, Armstrong L, Houghton R, Aitken S, Nyimbili E, Ewings S, Lillie PJ, Clark TW. Routine molecular point-of-care testing for respiratory viruses in adults presenting to hospital with acute respiratory illness (ResPOC): a pragmatic, open-label, randomised controlled trial. Lancet Respir Med. 2017 May;5(5):401-411. doi: 10.1016/S2213-2600(17)30120-0. Epub 2017 Apr 6. — View Citation

Ho YII, Wong AH, Lai RWM. Comparison of the Cepheid Xpert Xpress Flu/RSV Assay to in-house Flu/RSV triplex real-time RT-PCR for rapid molecular detection of Influenza A, Influenza B and Respiratory Syncytial Virus in respiratory specimens. J Med Microbiol. 2018 Nov;67(11):1576-1580. doi: 10.1099/jmm.0.000841. Epub 2018 Sep 12. — View Citation

Popowitch EB, Miller MB. Comparison of the Xpert Flu/RSV XC and Xpress Flu/RSV Assays. J Clin Microbiol. 2018 Jul 26;56(8). pii: e00278-18. doi: 10.1128/JCM.00278-18. Print 2018 Aug. — View Citation

Soto M, Sampietro-Colom L, Vilella A, Pantoja E, Asenjo M, Arjona R, Hurtado JC, Trilla A, Alvarez-Martínez MJ, Mira A, Vila J, Marcos MA. Economic Impact of a New Rapid PCR Assay for Detecting Influenza Virus in an Emergency Department and Hospitalized Patients. PLoS One. 2016 Jan 20;11(1):e0146620. doi: 10.1371/journal.pone.0146620. eCollection 2016. — View Citation

Trabattoni E, Le V, Pilmis B, Pean de Ponfilly G, Caisso C, Couzigou C, Vidal B, Mizrahi A, Ganansia O, Le Monnier A, Lina B, Nguyen Van JC. Implementation of Alere i Influenza A & B point of care test for the diagnosis of influenza in an ED. Am J Emerg Med. 2018 Jun;36(6):916-921. doi: 10.1016/j.ajem.2017.10.046. Epub 2017 Oct 18. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time of care in the adult emergency department	Emergency care time, calculated from the time of first medical-care contact to the time of release of the adults emergency department.; This time will be calculated from the data collected on the standardized questionnaire	through study completion, an average of 1 week
Secondary	Prescription of antibiotics initiated at the adults emergency department	nature of antibiotics	within 72 hours after taking care of the patient
Secondary	Duration of the prescription of antibiotics initiated at the adults emergency department	duration of treatment (day)	within 72 hours after taking care of the patient
Secondary	Posology of antibiotics initiated at the adults emergency department	posology (mg)	within 72 hours after taking care of the patient
Secondary	Costs of antibiotics initiated at the adults emergency department	associated costs (euros)	within 72 hours after taking care of the patient
Secondary	Prescription of antiviral initiated in adults emergency department	nature of antiviral prescription	within 72 hours after taking care of the patient
Secondary	Duration of the specific antiviral prescription initiated in adults emergency department	duration of treatment (day)	within 72 hours after taking care of the patient
Secondary	Costs of specific antiviral prescription initiated in adults emergency department	associated costs (euros)	within 72 hours after taking care of the patient
Secondary	Type of prescription of imaging tests at the adults emergency department	type of examinations related to the patient respiratory pathology	within 72 hours after taking care of the patient
Secondary	Number of prescription of imaging tests at the adults emergency department	Number of examinations related to the patient respiratory pathology	within 72 hours after taking care of the patient
Secondary	Costs of the prescription of imaging tests at the adults emergency department	Costs of examinations related to the patient respiratory pathology (euros)	within 72 hours after taking care of the patient
Secondary	Type of prescription of biology examinations	type of laboratory examinations related to respiratory pathology	within 72 hours after taking care of the patient
Secondary	Number of prescription of biology examinations	Number of laboratory examinations related to respiratory pathology	within 72 hours after taking care of the patient
Secondary	Costs of prescription of biology examinations	Costs of laboratory examinations related to respiratory pathology (euros)	within 72 hours after taking care of the patient

External Links

•   Information on Rapid Molecular Assays, RT-PCR, and other Molecular Assays for Diagnosis of Influenza Virus Infection
•   Nucleic Acid Detection Based Tests
•   Procédure actualisée de prise en charge globale d'un patient suspect de grippe saisonnière